3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
2
Phase 4
1
Status
Active not recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
22
Lymphoma, Follicular
6
Lymphoma
4
Lymphoma, Non-Hodgkin
3
Neoplasms
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, B-Cell
2
Tumor Lysis Syndrome
1
Recurrence
1
Neoplasm, Residual
1
Leukemia
1
Disease
1
Chromosome 17 deletion
1
Interventions
ofatumumab
3
venetoclax
2
pirtobrutinib
2
obinutuzumab
2
ibrutinib
2
Chlorambucil
2
acalabrutinib
1
Tablets
1
Observation
1
Cholecalciferol
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, B-Cell
×
obinutuzumab
×
Clear all
NCT04608318
2026-04-30
CLL17
German CLL Study Group
Phase 3
Active not recruiting
897 enrolled
NCT03836261
2024-12-27
AMPLIFY
Acerta Pharma BV
Phase 3
Active not recruiting
984 enrolled
1 FDA